메뉴 건너뛰기




Volumn 93, Issue 10, 2006, Pages 991-999

HER-2/neu positive breast cancer: How to prescribe adjuvant trastuzumab (Herceptin®)?;Cancer du sein surexprimant l'oncoprotéine Her2/Neu: Comment prescrire le trastuzumab (Herceptin®) en situation adjuvante?

Author keywords

Adjuvant treatment; Breast cancer; HER2; Trastuzumab

Indexed keywords

MONOCLONAL ANTIBODY; TAXANE DERIVATIVE; TRASTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

EID: 33750681662     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2006.0032     Document Type: Review
Times cited : (7)

References (41)
  • 1
    • 0021281324 scopus 로고
    • Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
    • Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 1984; 307: 521-7.
    • (1984) Nature , vol.307 , pp. 521-527
    • Downward, J.1    Yarden, Y.2    Mayes, E.3    Scrace, G.4    Totty, N.5    Stockwell, P.6
  • 2
    • 37049183697 scopus 로고
    • Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3    Levin, W.J.4    Ullrich, A.5    McGuire, W.L.6
  • 3
    • 0026502860 scopus 로고
    • Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer
    • Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-21.
    • (1992) Br J Cancer , vol.65 , pp. 118-121
    • Wright, C.1    Nicholson, S.2    Angus, B.3    Sainsbury, J.R.4    Farndon, J.5    Cairns, J.6
  • 4
    • 0026625217 scopus 로고
    • Prognostic importance of c-erbB-2 expression in breast cancer
    • International (Ludwig) Breast Cancer Study Group
    • Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-56.
    • (1992) J Clin Oncol , vol.10 , pp. 1049-1056
    • Gusterson, B.A.1    Gelber, R.D.2    Goldhirsch, A.3    Price, K.N.4    Save-Soderborgh, J.5    Anbazhagan, R.6
  • 6
    • 0029991439 scopus 로고    scopus 로고
    • Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
    • Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44.
    • (1996) J Clin Oncol , vol.14 , pp. 737-744
    • Baselga, J.1    Tripathy, D.2    Mendelsohn, J.3    Baughman, S.4    Benz, C.C.5    Dantis, L.6
  • 11
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3    Fuchs, H.4    Paton, V.5    Bajamonde, A.6
  • 12
    • 22344446208 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab combined with docetaxel in patients with HER2-positive metastatic breast cancer given as first-line treatment: Results of a randomized phase II trial (M77001)
    • Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with HER2-positive metastatic breast cancer given as first-line treatment: results of a randomized phase II trial (M77001). J Clin Oncol 2005; 23: 4265-74.
    • (2005) J Clin Oncol , vol.23 , pp. 4265-4274
    • Marty, M.1    Cognetti, F.2    Maraninchi, D.3    Snyder, R.4    Mauriac, L.5    Tubiana-Hulin, M.6
  • 13
    • 26844559765 scopus 로고    scopus 로고
    • Trastuzumab in the treatment of breast cancer
    • Hortobagyi G. Trastuzumab in the treatment of breast cancer. N Engl J Mol 2005; 353: 1734-6.
    • (2005) N Engl J Mol , vol.353 , pp. 1734-1736
    • Hortobagyi, G.1
  • 14
    • 33344478381 scopus 로고    scopus 로고
    • Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: The FinHer trial
    • Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T, Kataja V, Asola R, et al. Trastuzumab in combination with docetaxel or vinorelbine as adjuvant treatment of breast cancer: the FinHer trial. N Engl J Med 2006; 354: 809-20.
    • (2006) N Engl J Med , vol.354 , pp. 809-820
    • Joensuu, H.1    Kellokumpu-Lehtinen, P.-L.2    Bono, P.3    Alanko, T.4    Kataja, V.5    Asola, R.6
  • 15
    • 33645720799 scopus 로고    scopus 로고
    • Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study
    • abstract
    • Slamon D. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 91: 1[abstract].
    • (2005) Breast Cancer Res Treat , vol.91 , pp. 1
    • Slamon, D.1
  • 16
    • 0033118889 scopus 로고    scopus 로고
    • Inhibition effects of combinations of Her-2/neu antibody and chemotherapeutic agents used for treatment of breast cancers
    • Pergam M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, et al. Inhibition effects of combinations of Her-2/neu antibody and chemotherapeutic agents used for treatment of breast cancers. Oncogene 1999; 18: 2241-51.
    • (1999) Oncogene , vol.18 , pp. 2241-2251
    • Pergam, M.1    Hsu, S.2    Lewis, G.3    Pietras, R.4    Beryt, M.5    Sliwkowski, M.6
  • 17
    • 31444451572 scopus 로고    scopus 로고
    • Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?
    • Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 2006; 94: 259-67.
    • (2006) Br J Cancer , vol.94 , pp. 259-267
    • Arnould, L.1    Gelly, M.2    Penault-Llorca, F.3    Benoit, L.4    Bonnetain, F.5    Migeon, C.6
  • 18
    • 19344364880 scopus 로고    scopus 로고
    • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
    • Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
    • (2005) Lancet , vol.365 , pp. 1687-1717
  • 19
    • 0036099675 scopus 로고    scopus 로고
    • ErbB2 is essential in the prevention of dilated cardiomyopathy
    • Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-65.
    • (2002) Nat Med , vol.8 , pp. 459-465
    • Crone, S.A.1    Zhao, Y.Y.2    Fan, L.3    Gu, Y.4    Minamisawa, S.5    Liu, Y.6
  • 20
    • 33746326116 scopus 로고    scopus 로고
    • Severity of cardiovascular disease in women: Relation with exposure to endogenous estrogen
    • Saltiki K, Doukas C, Kanakakis J, Anastasiou H, Mantzou E, Alevizaki M. Severity of cardiovascular disease in women: relation with exposure to endogenous estrogen. Maturitas 2006; 55: 51-7.
    • (2006) Maturitas , vol.55 , pp. 51-57
    • Saltiki, K.1    Doukas, C.2    Kanakakis, J.3    Anastasiou, H.4    Mantzou, E.5    Alevizaki, M.6
  • 21
    • 33750990973 scopus 로고    scopus 로고
    • Collectif. Paris: Ed Inserm
    • Collectif. France: portrait social. Paris: Ed Inserm, 2006.
    • (2006) France: Portrait Social
  • 22
    • 0012643984 scopus 로고    scopus 로고
    • Phase III comparative study of trastuzumab and paclitaxel with or without carboplatin in patients with Her-2/neu positive advanced breast cancer
    • Robert N, Leyland-Jones B, Asmar L, Belt R, Illegbodu D, Loesch D, et al. Phase III comparative study of trastuzumab and paclitaxel with or without carboplatin in patients with Her-2/neu positive advanced breast cancer. Breast Cancer Res Treat 2002; 76: S7.
    • (2002) Breast Cancer Res Treat , vol.76
    • Robert, N.1    Leyland-Jones, B.2    Asmar, L.3    Belt, R.4    Illegbodu, D.5    Loesch, D.6
  • 23
    • 33749629577 scopus 로고    scopus 로고
    • Adjuvant radiotherapy and trastuzumab, in stage I-IIA breast cancer: Toxicity and data from North Central Cancer Treatment Group phase III trial N9831
    • abstract
    • Halyard MY, Pisansky TM, Solin LJ, Marks LB, Pierce LJ, Dueck A, et al. Adjuvant radiotherapy and trastuzumab, in stage I-IIA breast cancer: toxicity and data from North Central Cancer Treatment Group phase III trial N9831. Proc Clin Oncol 2006; 24: 523 [abstract].
    • (2006) Proc Clin Oncol , vol.24 , pp. 523
    • Halyard, M.Y.1    Pisansky, T.M.2    Solin, L.J.3    Marks, L.B.4    Pierce, L.J.5    Dueck, A.6
  • 24
    • 33750952036 scopus 로고    scopus 로고
    • Concurrent administration of weekly trastuzumab and adjuvant breast radiotherapy increases skin, esophageal, and cardiac acute toxicities
    • abstract
    • Belkacemi Y, Gligorov J, Laharie-Mineur O, Marsiglia H, Ozsahin MO, Azria D. Concurrent administration of weekly trastuzumab and adjuvant breast radiotherapy increases skin, esophageal, and cardiac acute toxicities. Proc J Clin Oncol 2006; 24: 630 [abstract].
    • (2006) Proc J Clin Oncol , vol.24 , pp. 630
    • Belkacemi, Y.1    Gligorov, J.2    Laharie-Mineur, O.3    Marsiglia, H.4    Ozsahin, M.O.5    Azria, D.6
  • 25
    • 4744342405 scopus 로고    scopus 로고
    • Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: Practice is culture driven rather than evidence based
    • Taghian A, Jagsi R, Makris A, Goldberg S, Ceilley, Grignon L, et al. Results of a survey regarding irradiation of internal mammary chain in patients with breast cancer: practice is culture driven rather than evidence based. Int J Radiat Oncol Biol 2004; 60: 706-14.
    • (2004) Int J Radiat Oncol Biol , vol.60 , pp. 706-714
    • Taghian, A.1    Jagsi, R.2    Makris, A.3    Goldberg, S.4    Ceilley5    Grignon, L.6
  • 26
    • 0346874162 scopus 로고    scopus 로고
    • Anti-EGF receptors and radiation therapy: Current translational research and early clinical trials
    • Azria D, Larbouret C, Robert B, Culine S, Ychou M, Verrelle P, et al. Anti-EGF receptors and radiation therapy: current translational research and early clinical trials. Bull Cancer 2003; 90: 202-12.
    • (2003) Bull Cancer , vol.90 , pp. 202-212
    • Azria, D.1    Larbouret, C.2    Robert, B.3    Culine, S.4    Ychou, M.5    Verrelle, P.6
  • 27
    • 0033559619 scopus 로고    scopus 로고
    • Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
    • Pietras RJ, Poen JC, Gallardo D, Wongvipat PN, Lee HJ, Slamon DJ. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res 1999; 59: 1347-55.
    • (1999) Cancer Res , vol.59 , pp. 1347-1355
    • Pietras, R.J.1    Poen, J.C.2    Gallardo, D.3    Wongvipat, P.N.4    Lee, H.J.5    Slamon, D.J.6
  • 28
    • 33750990671 scopus 로고    scopus 로고
    • Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer
    • abstract
    • Bellon JR, Gover MT, Burstein HJ, Harris JR, Harris LN. Concurrent trastuzumab and radiation therapy (RT) in the adjuvant treatment of breast cancer. Int J Radiat Oncol Biol 2005; 63: 91 [abstract].
    • (2005) Int J Radiat Oncol Biol , vol.63 , pp. 91
    • Bellon, J.R.1    Gover, M.T.2    Burstein, H.J.3    Harris, J.R.4    Harris, L.N.5
  • 29
    • 17144371333 scopus 로고    scopus 로고
    • Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
    • Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23: 2162-71.
    • (2005) J Clin Oncol , vol.23 , pp. 2162-2171
    • Baselga, J.1    Carbonell, X.2    Castaneda-Soto, N.J.3    Clemens, M.4    Green, M.5    Harvey, V.6
  • 30
    • 0035160313 scopus 로고    scopus 로고
    • Cardiotoxicity in signal transduction therapeutics: Erb2 antibodies and the heart
    • Schneider JW, Chang AW, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erb2 antibodies and the heart. Semin Oncol 2001; 28: 18-26.
    • (2001) Semin Oncol , vol.28 , pp. 18-26
    • Schneider, J.W.1    Chang, A.W.2    Rocco, T.P.3
  • 31
    • 0034471831 scopus 로고    scopus 로고
    • Myocyte survival patways and cardiomyopathy: Implications of trastuzumab cardiotoxicity
    • Chien KR. Myocyte survival patways and cardiomyopathy: implications of trastuzumab cardiotoxicity. Semin Oncol 2001; 27: 9-14.
    • (2001) Semin Oncol , vol.27 , pp. 9-14
    • Chien, K.R.1
  • 32
    • 0037007076 scopus 로고    scopus 로고
    • Modulation of anthracyclines-induced myofibrillar disarray in rat ventricular myocytes by neuroglin 1-beta and anti-erb2: Potential mechanism for trastuzumab-induced cardiotoxicity
    • Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM. Modulation of anthracyclines-induced myofibrillar disarray in rat ventricular myocytes by neuroglin 1-beta and anti-erb2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 2002; 105: 1551-4.
    • (2002) Circulation , vol.105 , pp. 1551-1554
    • Sawyer, D.B.1    Zuppinger, C.2    Miller, T.A.3    Eppenberger, H.M.4    Suter, T.M.5
  • 33
    • 0141576783 scopus 로고    scopus 로고
    • Meeting highlights: Update international expert consensus on the primary therapy of early breast cancer
    • Goldhirsch A, Wood WC, Gelber RD. Coates AS, Thurlimann B, Senn HJ. Meeting highlights: update international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-65.
    • (2003) J Clin Oncol , vol.21 , pp. 3357-3365
    • Goldhirsch, A.1    Wood, W.C.2    Gelber, R.D.3    Coates, A.S.4    Thurlimann, B.5    Senn, H.J.6
  • 34
    • 33750973821 scopus 로고    scopus 로고
    • Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab (H)
    • abstract
    • Geyer CE, Bryant JL, Romond EH, Ewer MS, Keefe DL, Shannon RP, et al. Update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) → paclitaxel (T) vs. AC → T with trastuzumab (H). Proc J Clin Oncol 2006; 24: 581 [abstract].
    • (2006) Proc J Clin Oncol , vol.24 , pp. 581
    • Geyer, C.E.1    Bryant, J.L.2    Romond, E.H.3    Ewer, M.S.4    Keefe, D.L.5    Shannon, R.P.6
  • 35
    • 33344458106 scopus 로고    scopus 로고
    • Herceptin and the heart: Molecular modifier of cardiac failure
    • Chien KR. Herceptin and the heart: molecular modifier of cardiac failure. N Engl J Med 2006; 354: 789-90.
    • (2006) N Engl J Med , vol.354 , pp. 789-790
    • Chien, K.R.1
  • 36
    • 0037606000 scopus 로고    scopus 로고
    • Initial clinical experience with moderate deep-inspiration breath hold using an active breathing control device in the treatment of patients with left-sided breast cancer using external beam radiation therapy
    • Remouchamps VM, Letts N, Vicini FA, Sharpe MB, Kestin LL, Chen PY, et al. Initial clinical experience with moderate deep-inspiration breath hold using an active breathing control device in the treatment of patients with left-sided breast cancer using external beam radiation therapy. Int J Radiat Oncol Biol Phys 2003; 56: 704-15.
    • (2003) Int J Radiat Oncol Biol Phys , vol.56 , pp. 704-715
    • Remouchamps, V.M.1    Letts, N.2    Vicini, F.A.3    Sharpe, M.B.4    Kestin, L.L.5    Chen, P.Y.6
  • 37
    • 20044371012 scopus 로고    scopus 로고
    • MRI-based volumetric assessment of cardiac anatomy and dose reduction via active breathing control during irradiation for left-sided breast cancer
    • Krauss DJ, Kestin LL, Raff G. MRI-based volumetric assessment of cardiac anatomy and dose reduction via active breathing control during irradiation for left-sided breast cancer. Int J Radiat Oncol Biol Phys 2005; 61: 1243-50.
    • (2005) Int J Radiat Oncol Biol Phys , vol.61 , pp. 1243-1250
    • Krauss, D.J.1    Kestin, L.L.2    Raff, G.3
  • 38
    • 10044286214 scopus 로고    scopus 로고
    • Radiation toxicity to the heart: Physiopathology and clinical data
    • Giraud P, Cosset JM. Radiation toxicity to the heart: physiopathology and clinical data. Bull Cancer 2004; 91: 147-53.
    • (2004) Bull Cancer , vol.91 , pp. 147-153
    • Giraud, P.1    Cosset, J.M.2
  • 39
    • 10044264624 scopus 로고    scopus 로고
    • Anthracycline-induced cardiotoxicity
    • Petit T. Anthracycline-induced cardiotoxicity. Bull Cancer 2004; 91: 159-65.
    • (2004) Bull Cancer , vol.91 , pp. 159-165
    • Petit, T.1
  • 40
    • 10044242769 scopus 로고    scopus 로고
    • Cardiac dysfunction induced by trastuzumab
    • Campone M, Bourbouloux E, Fumoleau P. Cardiac dysfunction induced by trastuzumab. Bull Cancer 2004; 91: 166-73.
    • (2004) Bull Cancer , vol.91 , pp. 166-173
    • Campone, M.1    Bourbouloux, E.2    Fumoleau, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.